Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 12

Trial Status

Recruiting2

Role Distribution

Principal Investigator2
PI Rate100%

Activity Timeline

Clinical Trials (2)

NCT06741072Phase 1Recruiting
BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants
Chronic Kidney Disease, Stage 4Chronic Kidney Disease, Stage 5EBV-Related Lymphoproliferative Disorder+2 more
PrincipalinvestigatorStart date: 2026-06-28
NCT06672705Phase 1Recruiting
Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders
Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative DisorderEBV-Related Post-Transplant Lymphoproliferative DisorderRecurrent Monomorphic Post-Transplant Lymphoproliferative Disorder+3 more
PrincipalinvestigatorStart date: 2025-06-16

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Sarah Schrauben, MD, MSCE

University of Pennsylvania

Related
4 trials

Shared therapeutic areas:

Chronic Kidney Disease Stage 4Chronic Kidney Disease Stage 5
Similarity Score5%

Samantha S Santi, DS

Universidade Federal de Santa Maria

Related
1 trials

Shared therapeutic areas:

Chronic Kidney Disease Stage 5
Similarity Score3%

Darrel P Cohen, MD, PhD

Viracta Therapeutics

Related
2 trials

Shared therapeutic areas:

EBV-Related Lymphoproliferative Disorder
Similarity Score3%

George Chen

Roswell Park Cancer Institute

Related
2 trials

Shared therapeutic areas:

Post-Transplant Lymphoproliferative Disorder

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score3%

Ajay Gopal

Fred Hutch/University of Washington Cancer Consortium

Related
8 trials

Shared therapeutic areas:

Post-Transplant Lymphoproliferative Disorder

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score3%

Ryotaro Nakamura

City of Hope Medical Center

Related
10 trials

Shared therapeutic areas:

Post-Transplant Lymphoproliferative Disorder

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score3%

Gisella Lopez

Lucid Diagnostics

Related
2 trials

Shared therapeutic areas:

Chronic Kidney Disease Stage 5
Similarity Score3%

Bilal Omer, MD

Baylor College of Medicine

Related
7 trials

Shared therapeutic areas:

EBV-Related Lymphoproliferative Disorder

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score3%

Suman Wason, MD

Lexicon Pharmaceuticals, Inc.

Related
23 trials

Shared therapeutic areas:

Chronic Kidney Disease Stage 4
Similarity Score3%

Rodrigo DM Plentz, PhD

Federal University of Health Sciences of Porto Alegre

Related
9 trials

Shared therapeutic areas:

Chronic Kidney Disease Stage 5
Similarity Score3%

Publications (0)

No publications found for this investigator.

Clinical Trials (2)

Showing 2 of 2 trials

NCT06741072Phase 1PrincipalInvestigator

BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants

Chronic Kidney Disease, Stage 4Chronic Kidney Disease, Stage 5EBV-Related Lymphoproliferative Disorder+2 more
Recruiting
NCT06672705Phase 1PrincipalInvestigator

Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders

Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative DisorderEBV-Related Post-Transplant Lymphoproliferative DisorderRecurrent Monomorphic Post-Transplant Lymphoproliferative Disorder+3 more
Recruiting

All 2 trials loaded